Wirksamkeit und Sicherheit von Estetrol/Drospirenon bei Endometriose

R. Maria Clauss
2025 · doi:10.1055/a-2510-8241 · W6884570834
OA: closed CC0
Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-09-19 ⓘ

This paper evaluates the efficacy and safety of estetrol/drospirenone for managing endometriosis symptoms, prioritizing hormone therapy to reduce endometrial buildup and improve patient quality of life.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-09-19 · read from full text ⓘ

This article reviews the efficacy and safety of a combination therapy containing estetrol and drospirenone for the treatment of endometriosis. It highlights that endometriosis significantly impairs quality of life through symptoms such as pelvic pain, dysmenorrhea, and dyspareunia, making symptom reduction a primary clinical goal. The text notes that hormonal therapies utilizing estrogen and progestin are considered to have the highest priority in reducing endometrial tissue growth. This paper is centrally about endometriosis — specifically evaluating a novel hormonal contraceptive formulation for managing its associated pain and disease progression.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Endometriose schränkt die Lebensqualität der betroffenen Frauen enorm ein. Beckenschmerzen, Dysmenorrhö, Dyspareunie und Defäkationsprobleme sind ständige Störfaktoren des Wohlbefindens. Die Implementierung schmerzreduzierender Behandlungsregime ist oberstes Ziel der entsprechenden klinischen Forschung. Der Hormontherapie mit Östrogen/Progestin-Präparaten zur Reduktion des Endometriumaufbaus kommt dabei grundsätzlich der höchste Stellenwert zu.
Full text 963 characters · extracted from oa-doi-fallback · click to expand
Subscribe to RSS Please copy the URL and add it into your RSS Feed Reader. https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000020.xml Geburtshilfe Frauenheilkd 2025; 85(03): 234 DOI: 10.1055/a-2510-8241 DOI: 10.1055/a-2510-8241 GebFra Magazin Aktuell referiert Wirksamkeit und Sicherheit von Estetrol/Drospirenon bei Endometriose Authors Endometriose schränkt die Lebensqualität der betroffenen Frauen enorm ein. Beckenschmerzen, Dysmenorrhö, Dyspareunie und Defäkationsprobleme sind ständige Störfaktoren des Wohlbefindens. Die Implementierung schmerzreduzierender Behandlungsregime ist oberstes Ziel der entsprechenden klinischen Forschung. Der Hormontherapie mit Östrogen/Progestin-Präparaten zur Reduktion des Endometriumaufbaus kommt dabei grundsätzlich der höchste Stellenwert zu. Publication History Article published online: 05 March 2025 © 2025. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

die_deep_infiltrating

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

References (1)

  • (no identifier) via openalex

Source provenance

openalex
last seen: 2026-05-11T05:27:43.641679+00:00
License: CC0 · commercial use OK